Endovia Health Sciences (EDVA) Revenue Growth (5y) (2017 - 2026)
Powered by 
Analysis
Endovia Health Sciences (EDVA) Revenue Growth (5y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.50 Bn | 133.65 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.53 Bn | 78.54 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.05 Bn | 59.86 Bn | 1.37 Bn |
| 4 | Moderna | 57.11 Bn | 51.98 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.71 Bn | 44.71 Bn | - |
| 6 | BeOne Medicines | 40.40 Bn | 35.31 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.36 Bn | 32.05 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.16 Bn | 27.32 Bn | - |
| 9 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn |
| 10 | Endovia Health Sciences | 801,166.21 | 558,464.21 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -71.36% |
| Dec 31, 2025 | -18.51% |
| Sep 30, 2025 | -10.72% |
| Jun 30, 2025 | -15.51% |
| Mar 31, 2025 | -9.34% |
| Dec 31, 2024 | -153.01% |
| Sep 30, 2024 | 26.33% |
| Jun 30, 2024 | 89.55% |
| Mar 31, 2024 | 256.78% |
| Dec 31, 2023 | 55.38% |
| Sep 30, 2023 | 75.05% |
| Jun 30, 2023 | 71.05% |
| Mar 31, 2023 | 76.02% |
| Dec 31, 2022 | 98.44% |
| Sep 30, 2022 | 72.48% |
| Jun 30, 2022 | 84.48% |
| Mar 31, 2022 | 79.61% |
| Dec 31, 2021 | 54.00% |
| Sep 30, 2021 | 65.72% |
| Jun 30, 2021 | 70.84% |